- Home
- IBIO vs COCH Comparison
IBIO vs COCH Comparison
Compare IBIO & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IBIO | COCH |
|---|---|---|
| Founded | 2008 | 1995 |
| Country | United States | United States |
| Employees | N/A | 42 |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.2M | 59.7M |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | IBIO | COCH |
|---|---|---|
| Price | $1.71 | $0.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $4.75 | ★ $9.50 |
| AVG Volume (30 Days) | ★ 1.1M | 334.4K |
| Earning Date | 05-01-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $0.36 |
| 52 Week High | $4.19 | $1.91 |
Technical Indicators
Market Signals| Indicator | IBIO | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 31.86 | 41.99 |
| Support Level | $1.70 | $0.36 |
| Resistance Level | $1.81 | $0.90 |
| Average True Range (ATR) | 0.21 | 0.09 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 20.91 | 7.22 |
Price Performance
Historical ComparisonAbout IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.